HC Wainwright reiterated coverage on ReWalk Robotics with a new price target
$RWLK
Industrial Specialties
Health Care
HC Wainwright reiterated coverage of ReWalk Robotics with a rating of Buy and set a new price target of $3.50 from $2.50 previously
Save time and jump to the most important pieces.
HC Wainwright reiterated coverage of ReWalk Robotics with a rating of Buy and set a new price target of $3.50 from $2.50 previously
HC Wainwright & Co. reiterated coverage of ReWalk Robotics with a rating of Buy and set a new price target of $3.50 from $2.50 previously
8-K - ReWalk Robotics Ltd. (0001607962) (Filer)
8-K - ReWalk Robotics Ltd. (0001607962) (Filer)
8-K - ReWalk Robotics Ltd. (0001607962) (Filer)
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 22, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today applauded the introduction of a Senate companion bill to H.R. 6373, the VA Spinal Trauma Access to New Devices (STAND) Act. The Senate companion bill was introduced by Chairman of the Senate Veterans' Affairs Committee, Senator Jon Tester (D-MT), and the Ranking Member of that committee, Senator Jerry Moran (R-KS).
Reverse split initiated to regain compliance with Nasdaq listing requirements Financial guidance for 2024 and profitability target for 2026 on existing capital remain unchanged MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 13, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that effective with the open of the market on Friday, March 15, 2024, the Company will complete a 1-for-7 reverse
Randomized clinical trial demonstrates significant improvements in walking ability for patients receiving therapy with the ReStore Exo-Suit as compared to a matched control group receiving conventional stroke therapy. Additional study demonstrates that the improvements in walking speed and distance following high-intensity gait training with the ReStore Exo-Suit were maintained by individuals post-stroke 4 weeks after the intervention had concluded. Combined results highlight the clinical value of the ReStore Exo-Suit and its related breakthrough propulsion-augmenting technologies within the Lifeward product development pipeline. MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, M